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Editorial
Recent advances in the treatment of musculoskeletal tumors in Japan
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In Japan, the greatest medical advances in the treatment 
of malignant musculoskeletal tumors during the past 40 
years have been made in high-dose chemotherapy and 
other related treatments, including bone marrow trans-
plantation and gene recombinant therapy. While high-
dose chemotherapy can diminish or resolve lung 
metastases that are already present at the fi rst visit in 
some cases, extensive tumor resection or removal of 
lung metastases is eventually necessary.
Chemotherapy can be very effective; when there has 
been an effective response most of the tumor tissues are 
usually necrotized, and intralesional removal and adju-
vant therapy are attempting with combined bone graft 
or artifi cial bone plombage. However, long-term results 
for the chemotherapy are not available yet. Surgical 
excision of low-grade malignant, well-differentiated 
chondrosarcomas is seen less frequently than before. 
These tumors can now be treated by removal with 
ethanol; liquid nitrogen freezing therapy; argon beam 
coagulation as adjuvant therapy; and fi lling with poly-
methyl methacrylate bone cement, beta-tricalcium 
phosphate (β-TCP), or hydroxyapatite.
The required surgical procedures include extensive 
wide resection and reconstructive surgery, taking into 
consideration whether loading is suitable, whether dead 
space is generated, and whether the cutaneous wound 
can be closed. The surgeon should determine the range 
of resection, taking into consideration the patient’s clin-
ical progress, imaging fi ndings, and pathological fi ndings. 
We assessed the margin of resection based on the extent 
of resection reported by Kawaguchi et al.1 and found 
that malignant musculoskeletal tumors could be resected 
longitudinally to at least 5 cm away from the tumor 
margin. The extent of transverse resection should be 
1 cm for thin fascia, 2 cm for thick fascia, and 1 cm for 
muscle. Transverse resection of at least 3–4 cm in total 
is required for high-grade malignant tumors. Any major 
vessels or nerves at the site of resection may require 
concomitant ablation or postoperative adjuvant therapy; 
the optimal postoperative treatment should be selected 
during surgery, based on the proximity of the tumor to 
vessels or nerves extent of separation between the 
tumor and the vessels or nerves. Matsumoto et al.2 
perform in situ preparation (ISP) in major vessels and 
nerves; if the tumor is easily separated, ethanol should 
be used 2–5 minutes before placing vinyl between 
nerves or vessels and normal tissue (1 cm margin: no 
recurrence).
Advances in chemotherapy boost the effect of neo-
adjuvant chemotherapy in cases of musculoskeletal 
tumors of the limbs. The affected limb can be preserved 
if high-dose chemotherapy is effective. An artifi cial joint 
is used for reconstruction. Owing to extensive tissue loss 
in the pelvic or hip regions, controllable joint systems 
are used near the femur. The outcome is relatively 
stable, and survival of 10 years or longer has been 
reported in some patients. Arthrodesis was used about 
20 to 30 years ago, when it was not yet possible to 
perform stable artifi cial joint arthroplasty. Around the 
same time, allogeneic bone transplantation was intro-
duced. Complications were reported in 30% of patients. 
Such transplants are useful in patients who do not 
require chemotherapy. In Japan, allogeneic bone trans-
plantation is diffi cult, and recycled bone is used. Various 
methods are available, such as curettage the largest part 
of the removed bone tumor and immersing the remain-
ing bone in frozen liquid nitrogen (15 min), or repairing 
the removed bone by applying high-dose radiation or a 
Pasteur water bath (60°C for 20 min) to it for internal 
fi xation. These procedures may have poor results 
without the concomitant use of a vascularized bone 
graft.
The timing of surgical treatment varies slightly among 
patients. In Japan, the usual course of treatment consists 
of two to three cycles of neoadjuvant chemotherapy, 
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surgery, and four to fi ve cycles of postoperative chemo-
therapy, in this order. Patients who develop infection 
after extensive tumor resection cannot receive postop-
erative chemotherapy, and amputation may be required. 
The risk of infection can be minimized by using a vas-
cularized fi bular graft, a vascularized iliac graft, or a 
musculocutaneous fl ap. In some cases, adequate chemo-
therapy is continued as long as it is effective and this 
leads to surgery as the fi nal step. A delay in postopera-
tive chemotherapy due to surgical complications must 
be avoided. Surgery after adequate neoadjuvant chemo-
therapy is highly recommended, particularly for the 
removal of trunk or pelvic tumors, total femoral replace-
ment, and in patients with lung metastases.
Advances in spinal surgery depend largely on 
advances in the instruments. After the application of a 
threadwire saw (T-saw) to tumor resection, as reported 
by Tomita and Kawahara,3 spinal tumors can be removed 
safely without severe stress on the tumors, while pro-
tecting the spinal cord. We employ a modifi ed T-saw4 
that was designed by adding some modifi cations to the 
T-saw. Sacral chordomas showing frequent recurrence 
were extremely diffi cult to remove surgically. Among 
our patients with such tumors, 11 patients had had the 
disease for at least 10 years. The survival time was 10 
years or longer in 6 patients; the survival rate was 55% 
by Kaplan-Meier analysis. One man (69 years old) died 
of another disease after a 6-year survival. Apart from 
this elder and high grade chordoma patients, approxi-
mately 65% of our patients survived the disease. Patients 
with concurrent bladder disorders have a high risk of 
pyelonephritis and may suffer from fecal incontinence; 
these problems can interfere with their employment. 
T-saw can shorten the surgery time, decrease the amount 
of blood loss, and allow nerves to be preserved to a 
lower level in comparison with conventional resection 
methods, reducing the recurrence rate and improving 
postoperative function. Carbon ion radiotherapy is less 
likely than surgery to cause functional impairment, par-
ticularly in cases of chordoma. Its long-term outcome 
after 10 years or longer is not available yet, and the 
therapy carries the risk of complications, such as skin 
disorders and neurogenic pain. The therapy is a good 
option for patients requiring extensive tumor removal 
that may result in impaired function or recurrence. 
However, surgical resection is recommended if the 
nerves at sacral level 3 and higher can be preserved.
In pediatric patients, osteosarcoma and Ewing’s 
sarcoma are the common malignant musculoskeletal 
tumors of tumor prosthesis. In these patients, neoadju-
vant chemotherapy is important. After surgical resec-
tion, an expanding tumor prosthesis is implanted, and 
many problems remain with the extension of tumor 
prosthesis. In children, unequal leg length causes a 
problem. Tsuchiya et al.5 reported limb lengthening by 
external skeletal fi xation in their patients, including 
both children and adults. For lesions in the diaphysis, a 
vascularized fi bular graft may be a favorable option.
Minimally invasive surgery is effective for benign 
tumors but involves such problems as the time required 
for surgery, and the risk of recurrence for aggressive 
tumors. This procedure is also applied to cases of malig-
nant tumors for which chemotherapy is extremely effec-
tive, as mentioned above.
As promising treatments, gene therapy and vaccine 
therapy have been shown to be effective for metastases 
from low-grade malignant tumors. Medical advances 
are limitless. We must make every effort to advance.
The 43rd Annual Musculoskeletal Tumor Meeting of 
the Japanese Orthopaedic Association, which is a tradi-
tional academic meeting, will be held on July 15 (Thurs-
day) and 16 (Friday), 2010, at the Keio Plaza Hotel 
Tokyo in Shinjuku, Tokyo, Japan. The theme of the 
meeting is “Challenges in the surgical treatment of dif-
fi cult malignant musculoskeletal tumors and training 
of young doctors.” The original intention of surgical 
therapy is to save patients suffering from diseases. We 
must face diffi cult cases of malignant tumors. The surgi-
cal techniques needed for these challenges are not easy. 
Each surgeon should not only comprehend the patient’s 
general condition, but also the tumor characteristics, 
imaging fi ndings, and histopathological data. Ligation of 
a single vessel is an important step. The surgeon should 
perform surgery responsibly until the last, though it is 
long time surgery. Such an attitude can lead to success-
ful surgery. The abstracts of the meeting include outlines 
of many changes in diagnostic methods and new treat-
ments. At this meeting, we will be pleased to transmit 
our enthusiasm as surgeons to young doctors, to prepare 
them for diffi cult surgery.
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